<DOC>
	<DOC>NCT00259337</DOC>
	<brief_summary>The present clinical study will assess the immunogenicity as the primary objective and the reactogenicity as the secondary objective of Aventis Pasteur's DTacP-IPV// PRP~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vaccination at 6, 10 and 14 weeks of age followed by a booster dose during the second year of life. Safety: This study will describe the safety after each dose of the primary series of the study's combined vaccine (Pentaxim™).</brief_summary>
	<brief_title>Immunogenicity and Safety of Pentaxim™ in an Indian Population</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 42 to 56 days inclusive on the day of inclusion Born at full term pregnancy (&gt; 37 weeks) with a birth weight ≥ 2.5 kg Informed consent form signed by the parent(s) or other legal representative Able to attend all scheduled visits and to comply with all trial procedures Participation in another clinical trial in the 4 weeks preceding the (first) trial vaccination Planned participation in another clinical trial during the present trial period Congenital or acquired immunodeficiency, immunosuppressive therapy such as longterm systemic corticosteroids therapy Systemic hypersensitivity to any of the vaccine components or history of a lifethreatening reaction to the trial vaccine or a vaccine containing the same substances Chronic illness at a stage that could interfere with trial conduct or completion. Blood or bloodderived products received in the past. Any vaccination preceding the trial vaccination (except BCG and hepatitis B) History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B or Haemophilus influenza type b (confirmed either clinically, serologically or microbiologically). Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis diseases or Haemophilus influenza type b infection with the trial vaccine or another vaccine. Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination History of/current seizures Febrile illness (rectal temperature ≥ 38.0°C or axillary temperature ≥ 37.4°C) or acute illness on the day of inclusion.</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>56 Days</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Diphteria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Polio</keyword>
	<keyword>Acellular Pertussis</keyword>
	<keyword>Hib</keyword>
	<keyword>Haemophilus influenzae type B</keyword>
</DOC>